PET/CT Predicts Response to HER2 Therapy in Metastatic Breast Cancer
A new imaging agent, 68Ga-ABY-025, can predict early metabolic response to HER2-targeted treatment in HER2-positive metastatic breast cancer patients, new research shows.
A new imaging agent, 68Ga-ABY-025, can predict early metabolic response to HER2-targeted treatment in HER2-positive metastatic breast cancer patients, new research shows.
A new pre-targeted radioimmunotherapy system, targeting the HER2 protein in ovarian cancer, has demonstrated potential in curing a lethal form of advanced intraperitoneal ovarian cancer with minimal side effects in a preclinical study.
The Center for Quantitative Cancer Imaging at Huntsman Cancer Institute in Salt Lake City announces that it is the first in the U.S. to install United Imaging's uMI Panorama PET/CT scanner.
Japanese scientists have developed an artificial intelligence model that accurately estimates a patient’s age, using chest radiographs of healthy individuals collected from multiple facilities
Read MoreUsing MRI as a screening test alongside PSA density allowed detection of cancers that would have been missed by the blood test alone, according to new research out of London.
Read MoreResearchers at the University of Wisconsin, Madison, have achieved a breakthrough in the production of scandium radioisotopes, a development with profound implications for the future of medical imaging and cancer treatment.
Read MoreAn automated model, trained and evaluated on Dixon MRI scans of adolescents, holds the potential to facilitate large-scale studies on abdominal fat distribution and its clinical implications among youth.
Read MoreNew research highlights that PSMA PET/CT imaging can potentially diagnose advanced prostate cancer and guide treatment decisions without the need for biopsies in elderly patients, offering accurate staging data and potentially reducing complications associated with biopsies.
Read More